Sun Pharma said to face FDA quality questions; Stada signs up to market Neupogen biosim in Europe;

@FiercePharma: Still trending on our website (in a big way): Teva profile as No. 1 on our Top 10 Generics Makers list. Profile | Follow @FiercePharma

@EricPFierce: What drugs are up for grabs by generic makers next year? Here's the FiercePharma list of 2014 patent losses. Report | Follow @EricPFierce

@CarlyHFierce: Biogen's Tecfidera drives rosy Q3 results, higher forecast. More | Follow @CarlyHFierce

> India's Sun Pharmaceutical saw shares fall after Bloomberg reported FDA worries about quality at its U.S. subsidiary Caraco. Report

> Germany's Stada signed on with Apotex to market a biosimilar version of Amgen's ($AMGN) Neupogen in Europe; the knockoff version will be sold under the brand name Grastofil. Report

> Lundbeck won FDA approval to market its seizure drug Sabril for use in children 10 years of age and older. Report

> The FDA's decision to tighten restrictions on painkiller prescribing has been coming for many years. Report (sub. req.)

> When the FDA approved Zogenix's ($ZGNX) new painkiller Zohydro last week, it did not require the drug to have built-in mechanisms to deter abuse. Report

Medical Device News

@FierceMedDev: Abbott's MitraClip heart valve device gains FDA's long-awaited blessing. ICYMI Friday | Follow @FierceMedDev

@MarkHFierce: GE healthcare is aiming for a 2014 launch for its new Alzheimer's imaging agent. More from FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: A blog post from the FDA late last week highlighted the agency's efforts to regulate nanotechnology. Blog | Follow @MichaelGFierce

> Boston Scientific bags CE mark for heart valve as market crowds. News

> Bill would clarify FDA oversight over mobile medical apps. Story

> Edwards joins Middle Peak financing to gain stake in mitral device race. More

Biotech News

@FierceBiotech: CytomX 'probody' kills pancreatic cancer cells, leaves healthy tissue intact. Story from FierceBiotech Research | Follow @FierceBiotech

@JohnCFierce: UPDATED: FDA overrides Zohydro panel, approves pure hydrocodone pain med. Story | Follow @JohnCFierce

@DamianFierce: ICYMI: Aerie prices $67M IPO and becomes 40th biotech to go public this year. Story | Follow @DamianFierce

@EmilyMFierce: GMOs Versus Overuse Of Antibiotics: Which Is The Greater Evil? More from Forbes | Follow @EmilyMFierce

> Bristol-Myers takes shot at Humira as arthritis drug aces Phase IIb. Story

> Bullish Actelion once again heats up as a possible takeover target. Item

> Bristol-Myers adds promising survival update on breakthrough cancer drug. Report

> Gilead sweeps FDA panel vote for pioneering hep C drug sofosbuvir. Article

CRO News

> InVentiv opens U.K. hub as EU demand climbs. More

> Dendreon picks CMO PharmaCell to make Provenge in Europe. Item

> Novum reaches into N. Dakota for clinical trials. Article

> SRI sets sights on CRO growth with Virginia expansion. Story

> Icon boosts outlook after 19% sales jump. Report

> CRO Atheris hooks up with Debiopharm for cancer R&D. More

Biotech IT News

> Medidata eyes Novartis' business after inking Alcon deal. More

> Broad Institute to offer sequencing services after receiving CLIA nod. Item

> VCs tap Amgen-acquired genomics database to power startup. Report

> Oxford Nanopore readying for user tests of handheld sequencing device. Story

> Amazon, Baylor and DNAnexus team up for huge sequencing project. Article

And Finally... On the latest list of India's super-rich, the pharma business accounted for 11% of the entries. Report

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.